Survival of women with pregnancy-associated breast cancer according to clinical characteristics
A propensity score matching study

Hongki Gwak, MDa, Sang Seok Woo, MDb, Eun-Sook Lee, MD, PhDc, Min Ho Park, MD, PhDd, Seokwon Lee, MD, PhD, Hyun Jo Youn, MD, PhD, Seho Park, MD, In Suck Suh, MDb, Seong Hwan Kim, MD, PhD* •

Abstract
In recent years, postponing childbearing has increased the prevalence of pregnancy-associated breast cancer (PABC). PABC has a poorer prognosis than breast cancer not associated with pregnancy (non-PABC) due to delayed diagnosis and aggressive subtype. Additionally, pregnancy itself predicts a poor prognosis; but, this is a subject of debate. Thus, we analyzed the effects of known prognostic factors and pregnancy on the prognosis of PABC. We retrospectively analyzed women aged 20 to 49 years who were diagnosed with breast cancer (BC) between 1989 and 2014. Patients were distributed into PABC and non-PABC groups, and 1:4 propensity score matching was performed to adjust for baseline characteristics. Primary endpoints were overall survival (OS) and BC-specific survival (BCSS). Secondary endpoint was the difference in prognosis according to BC subtype. Of the 34,970 recruited patients with BC, 410 (1.2%) had PABC. Patients with PABC were younger and tended to have triple-negative BC (TNBC) subtype than non-PABC patients. The 1640 matched non-PABC patients showed a significantly worse mean survival rate than the unmatched non-PABC patients. Patients with PABC had a significantly worse OS and BCSS than those with non-PABC. In multivariate analyses, patients with PABC of luminal B (Ki-67 ≥14.0%) and TNBC subtypes had worse OS and survival rate than the unmatched non-PABC patients. Patients with PABC had a significantly worse OS and BCSS than those with non-PABC. Patients with PABC had poorer prognosis than non-PABC patients after adjusting for several prognostic factors. This difference was particularly significant in patients with the luminal B and TNBC subtypes.

Abbreviations: BC = breast cancer, BCSS = breast cancer-specific survival, ER = estrogen receptor, HER2 = human epidermal growth factor receptor 2, non-PABC = breast cancer not associated with pregnancy, OS = overall survival, PABC = pregnancy-associated breast cancer, PR = progesterone receptor, TNBC = triple-negative breast cancer

1. Introduction
Pregnancy-associated breast cancer (PABC) is defined as breast cancer (BC) that occurs during pregnancy or within 1 year after delivery.[1] As the age at childbirth increases, the incidence of PABC also increases.[2–4] PABC is a complex disease affecting patients, their families, and clinicians. Treatment is challenging for clinicians because the goal is to ensure the safety of both the mother and baby. Patients with PABC tend to be younger than breast cancer not associated with pregnancy (non-PABC) patients and often present with more advanced disease, leading to worse prognosis. However, some studies have suggested that pregnancy itself predicts a poor prognosis of PABC. These conclusions are controversial, but it is difficult to conduct randomized controlled studies due to the rarity of this disease and ethical issues. We conducted a retrospective study using propensity score matching (PSM) to analyze the prognosis of PABC and evaluate effects of known prognostic factors.

2. Methods
2.1. Compliance with ethical standards
The study protocol was approved by the Institutional Review Board of the Catholic University of Korea (VC21ZADI0234;
Seoul, South Korea). All patient data were collected by the Korean Breast Cancer Society. All patients provided written informed consent for the storage and use of their information for research purposes.

2.2. Data source and study population
This retrospective study was based on prospectively collected data from patients who underwent BC surgery at 102 general hospitals. Women aged 20 to 49 years who were diagnosed with BC and underwent surgery between 1989 and 2014 were included in the study. Patients without estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 results, that are necessary immunohistochemistry data for molecular subtype classification, and patients without stage results, were excluded. PABC was defined as a diagnosis of BC during pregnancy or within 1 year after delivery.

2.3. Subtypes
Immunohistochemistry was performed according to the local hospital practice. HER2-positivity was defined as either an immunohistochemical staining score of 3+ or HER2 amplification according to fluorescence in situ hybridization (HER2-to-chromosome centromere 17 ratio ≥2.0). Clinical and pathological tumor–node–metastasis stages were classified according to the sixth edition of the American Joint Committee on Cancer. Tumors were classified into the following five subtypes based on ER, PR, HER2, and Ki-67 statuses: luminal A (ER- and/or PR-positive, HER2-negative, and Ki-67 <14.0%), luminal B (hormone receptor-positive, HER2-negative, and Ki-67 ≥14.0%), luminal HER2 (hormone receptor-positive and HER2-positive), HER2 amplified (ER-negative, PR-negative, and HER2-positive), and triple-negative BC (TNBC; ER-negative, PR-negative, and HER2-negative).

2.4. Statistical analyses
Prior to statistical analyses, a logistic regression model was used to select factors potentially affecting patient outcomes, including age, surgical method, cancer stage, BC subtype, tumor pathological stage, and history of chemotherapy. The propensity score for each factor was calculated using a regression model, and the closest propensity score was based on a control ratio of 1:4 using the nearest-neighbor algorithm approach with no replacement. The chi-square test was used to compare baseline characteristics between the patient groups. Survival curves were generated using the Kaplan–Meier method, and survival differences were analyzed using the log-rank test. We calculated the hazard ratios and 95% confidence intervals for BC-specific survival (BCSS) and overall survival (OS) using the Cox proportional hazards model. Statistical analyses were performed using R software version 4.0.2 (R Core Team [2013] R: A language and environment for statistical computing, R Foundation for Statistical Computing, Vienna, Austria).

Figure 1. Flow chart of patient population. Data collection was performed between 1989 and 2014. ER = estrogen receptor, HER2 = human epidermal growth factor receptor 2, PR = progesterone receptor.
and environment for statistical computing. R Foundation for Statistical Computing, http://www.R-project.org/, Vienna, Austria). A \( P < .05 \) was considered to be statistically significant.

3. Results

3.1. Baseline characteristics

Of the 114,884 women with BC, 74,914 were excluded, and 34,970 were finally included in the analysis (Fig. 1). Of the patients included in the analysis, 410 (1.2\%) had PABC. The PABC group was significantly younger than non-PABC group, with a mean age of 34.4 (±5.1) versus 42.2 (±5.3) years (\( P < .001 \)). The number of patients aged <35 years was 60\% in the PABC group, that was significantly higher than that in non-PABC group (9.8\%) (\( P < .001 \)). Patients with PABC had a significantly more advanced stage and higher histological grade than non-PABC patients. In non-PABC patients, stage I accounted for 39.6\% and stage IV accounted for 1.4\%; but, in PABC patients, stage I accounted for 22.4\% and stage IV accounted for 5.6\% (\( P < .001 \)). The luminal \( A \) subtype had a significantly lower proportion (PABC 4.1\% vs non-PABC 15.2\%) and TNBC had significantly higher proportion in the PABC group (PABC 42.2\% vs non-PABC 17.4\%) than in non-PABC group (\( P < .001 \)). Chemotherapy was administered significantly more frequently in the PABC group than in non-PABC group (89.5\% vs 80.1\%, \( P < .001 \)). Variables showing a significant difference between the two groups, such as age, stage, tumor type, histologic grade, subtype, and chemotherapy, were corrected using PSM. The baseline characteristics of the patients before and after PSM are shown in Table 1.

3.2. Survival analyses

The mean follow-up duration was 87 months. After PSM, the OS and BCSS of the non-PABC group were significantly poorer than those of unmatched non-PABC group (both \( P < .001 \)). The OS and BCSS of the PABC group were significantly worse than those of matched non-PABC group (both \( P < .001 \) (Fig. 2).

3.3. Subgroup analyses

Cox regression analysis was performed on all variables used in the PSM. Patients with PABC showed unfavorable OS and BCSS for all variables in the univariate analysis (Figs. 3 and 4). Patients with PABC aged <35 years and with the luminal \( B \) or TNBC subtype had significantly worse OS and BCSS than the respective non-PABC patients (Figs. 3 and 4), consistent with the multivariate analyses (Table 2).

4. Discussion

Pregnancy and childbirth are considered effective for preventing BC. However, studies have reported a poor prognosis for BC.

### Table 1

**Clinical characteristics of patients before and after propensity-score matching.**

| Characteristics | Before propensity score matching, n (%) | After propensity score matching, n (%) | \( P \) value | Before propensity score matching, n (%) | After propensity score matching, n (%) | \( P \) value |
|-----------------|----------------------------------------|----------------------------------------|--------------|----------------------------------------|----------------------------------------|--------------|
| Age             |                                        |                                        |              |                                        |                                        |              |
| \(<35\)         | 246 (60.0)                             | 3396 (9.8)                             | \(<.001\)     | 246 (60.0)                             | 982 (59.9)                             | 1            |
| \(\geq35\)      | 164 (40.0)                             | 31164 (90.2)                           |              | 164 (40.0)                             | 638 (40.1)                             |              |
| Operation       |                                        |                                        |              |                                        |                                        |              |
| Breast-conserving | 211 (51.5)                             | 18,969 (54.9)                          | .178         | 211 (51.5)                             | 888 (54.1)                             | .347         |
| Mastectomy      | 199 (48.5)                             | 15,591 (45.1)                          |              | 199 (48.5)                             | 752 (45.9)                             |              |
| Stage*          |                                        |                                        |              |                                        |                                        |              |
| I               | 92 (22.4)                              | 13,692 (39.6)                          | \(<.001\)     | 92 (22.4)                              | 376 (22.9)                             | 292          |
| II              | 93 (22.7)                              | 5019 (14.5)                            |              | 93 (22.7)                              | 375 (22.9)                             |              |
| III             | 202 (49.3)                             | 15,372 (44.5)                          |              | 202 (49.3)                             | 831 (50.7)                             |              |
| IV              | 23 (5.6)                               | 477 (1.4)                              |              | 23 (5.6)                               | 58 (3.5)                               |              |
| Tumor type      |                                        |                                        |              |                                        |                                        |              |
| Ductal invasive | 387 (94.4)                             | 33,181 (96.0)                          | \(<.001\)     | 387 (94.4)                             | 1551 (94.6)                            | .972         |
| Lobular invasive| 5 (1.2)                                | 1055 (3.1)                             |              | 5 (1.2)                                | 21 (1.3)                               |              |
| Other           | 18 (4.4)                               | 324 (0.9)                              |              | 18 (4.4)                               | 68 (4.1)                               |              |
| Histological grade† |                                        |                                        |              |                                        |                                        |              |
| I               | 27 (7.8)                               | 5184 (16.9)                            | \(<.001\)     | 32 (9.1)                               | 131 (9.1)                              | .28          |
| II              | 113 (32.6)                             | 14,102 (46.1)                          |              | 113 (32.1)                             | 523 (36.5)                             |              |
| III             | 207 (59.7)                             | 11,321 (37.0)                          |              | 207 (58.8)                             | 779 (54.4)                             |              |
| Unknown         | 63                                     | 3953                                   |              | 58                                     | 207                                    |              |
| Subtype‡        |                                        |                                        |              |                                        |                                        |              |
| Luminal A       | 17 (4.1)                               | 5255 (15.2)                            | \(<.001\)     | 17 (4.1)                               | 70 (4.3)                               | 1            |
| Luminal B       | 128 (31.2)                             | 15,557 (45.0)                          |              | 128 (31.2)                             | 513 (31.3)                             |              |
| Luminal HER2     | 43 (10.5)                              | 4823 (14.0)                            |              | 43 (10.5)                              | 167 (10.2)                             |              |
| HER2            | 49 (12.0)                              | 2925 (8.5)                             |              | 49 (12.0)                              | 197 (12.0)                             |              |
| TNBC            | 173 (42.2)                             | 6000 (17.4)                            |              | 173 (42.2)                             | 693 (42.3)                             |              |
| Hormone therapy |                                        |                                        |              |                                        |                                        |              |
| Yes             | 150 (92.6)                             | 22,556 (88.0)                          | \(<.001\)     | 150 (92.6)                             | 627 (91.4)                             | .753         |
| No              | 12 (7.4)                               | 3079 (12.0)                            |              | 12 (7.4)                               | 150 (8.6)                              |              |
| Chemotherapy    |                                        |                                        |              |                                        |                                        |              |
| Yes             | 367 (89.5)                             | 27,668 (80.1)                          | \(<.001\)     | 367 (89.5)                             | 1483 (90.4)                            | .577         |
| No              | 43 (10.5)                              | 6892 (19.9)                            |              | 43 (10.5)                              | 157 (9.6)                              |              |

HER2 = human epidermal growth factor receptor 2; non-PABC = breast cancer not associated with pregnancy; PABC = pregnancy-associated breast cancer; TNBC = triple-negative breast cancer.

*TNM classification according to the 6th edition of the American Joint Committee on Cancer.

†The grade according to Bloom–Richardson17 was taken from local pathology reports.

‡Immunohistochemistry was performed according to local practice.
that develops 1 to 10 years after pregnancy,[4–6] BC that occurs 1 to 2 years after pregnancy has the worst prognosis and is usually defined as PABC,[7–9] although there are reports that the timing of pregnancy does not affect prognosis.[5,10]

PABC differs from non-PABC in terms of tumor biology and prognosis. PABC generally presents at an advanced stage. Regular BC screening in young women is rare, and breast congestion due to pregnancy and lactation may delay mass detection. Moreover, PABC is often associated with more aggressive subtypes than non-PABC, with higher rates of ER/PR-negative, HER2-positive, and TNBC subtypes.[3,4,11–13] In recent years, surgery and chemotherapy are actively performed and the survival of patients with PABC has markedly improved. However, chemotherapy cannot be administered during the first trimester of pregnancy, and hormonal and radiation therapies are only possible after childbirth.

In the present study, the PABC group had more aggressive subtypes, such as TNBC and HER2, and a higher stage and histological grade than non-PABC group, consistent with results of previous studies. After PSM of variables that potentially affect prognosis, the survival of non-PABC patients decreased, as expected. However, patients with PABC showed a worse prognosis than matched non-PABC patients. These results confirm that pregnancy itself is a predictor of poor prognosis.

During pregnancy and lactation, the levels of hormones such as estrogen, progesterone, insulin-like growth factor 1, prolactin, and oxytocin increase, that can increase tumor cell proliferation.[14,15] A weakened immune system during pregnancy and

Figure 2. Kaplan–Meier curves for overall survival (A) and breast cancer specific survival (B).
breast remodeling can also affect cancer growth and metastasis.\cite{12} However, despite several studies, the results are inconsistent owing to small population sizes and discrepancies in study methods.\cite{16} Therefore, the notion that PABC itself is associated with poor prognosis remains debatable.\cite{17}

The prognosis of BC depends on the molecular subtype.\cite{13,18} Differences between BC subtypes may explain the inconsistency in results of several studies that analyzed the prognosis of patients with PABC. However, there have been few studies on the prognosis of PABC according to subtype. It has been reported that prognosis differs only for the luminal B subtype in PABC than in non-PABC group.\cite{12} The present study showed that patients with PABC with luminal B and TNBC subtypes had poor prognoses.

Efforts are being made to minimize BC treatment to achieve optimal outcomes, avoiding over- or under-treatment.\cite{19} A careful selection of treatment tailored for each patient can provide a better prognosis and quality of life and ensure low therapeutic toxicity. The St. Gallen International Expert Consensus 2017 debated on decreasing and increasing the extent of treatments for early stage BC.\cite{20} Consensus has been reached on several topics, such as tumor biology, subtypes, genomic signatures, and special populations, but PABC has not been included in the consensus due to insufficient data. The present study provides an important basis for personalized onco logical treatment of patients with PABC. It is recommended to not reduce treatment for PABC. Moreover, an increased treatment should be considered for luminal B or TNBC subtypes for patients with PABC aged <35 years.

|                | PABC | non-PABC | Unadjusted Hazard Ratio (95% CI) | P Value |
|----------------|------|----------|---------------------------------|---------|
| Overall        | 410  | 1640     | 1.881 (1.502-2.354)             | <0.001  |
| Age < 35       | 246  | 982      | 1.968 (1.500-2.582)             | <0.001  |
| Age ≥35        | 164  | 658      | 1.733 (1.161-2.586)             | 0.007   |
| Operation      |      |          |                                 |         |
| BCS            | 211  | 894      | 2.256 (1.657-3.248)             | <0.001  |
| Mastectomy     | 199  | 752      | 1.661 (1.248-2.211)             | <0.001  |
| Stage I        | 92   | 376      | 3.312 (1.457-7.529)             | 0.003   |
| Stage II       | 93   | 375      | 1.876 (1.128-3.322)             | 0.015   |
| Stage III      | 202  | 831      | 1.805 (1.341-2.429)             | 0.007   |
| Stage IV       | 23   | 58       | 1.701 (0.936-3.091)             | 0.081   |
| Histologic grade |      |          |                                 |         |
| Grade I        | 32   | 131      | 1.129 (0.297-4.294)             | 0.859   |
| Grade II       | 113  | 523      | 1.584 (1.000-2.508)             | 0.05    |
| Grade III      | 207  | 779      | 1.542 (1.218-1.928)             | 0.007   |
| Tumor type     |      |          |                                 |         |
| Ductal         | 387  | 1551     | 1.877 (1.490-2.364)             | <0.001  |
| Lobular        | 5    | 21       | 1.776 (0.311-10.155)            | 0.518   |
| Others         | 18   | 68       | 1.962 (0.587-6.651)             | 0.274   |
| Subtype        |      |          |                                 |         |
| LumA           | 17   | 70       | 1.200 (0.379-3.805)             | 0.756   |
| LumB (Ki67)    | 128  | 513      | 2.238 (1.480-3.385)             | <0.001  |
| LumHER2        | 43   | 167      | 1.229 (0.539-2.035)             | 0.624   |
| HER2           | 49   | 197      | 1.413 (0.721-2.769)             | 0.315   |
| TNBC           | 173  | 603      | 2.066 (1.486-2.872)             | <0.001  |
| Chemotherapy   |      |          |                                 |         |
| Yes            | 367  | 1483     | 1.928 (1.534-2.424)             | <0.001  |
| No             | 43   | 157      | 1.660 (0.497-5.546)             | 0.41    |
| Hormone therapy |      |          |                                 |         |
| Yes            | 150  | 627      | 2.117 (1.431-3.130)             | <0.001  |
| No             | 12   | 49       | 1.879 (0.588-6.002)             | 0.287   |

Figure 3. Forest plot of the association of pregnancy with death from any cause in various subgroups after propensity-score matching. PABC = pregnancy-associated breast cancer.
This study has some limitations. First, we failed to evaluate the role of the delay in initiating chemotherapy; however, Loibl et al have reported that survival rate is not affected by delayed chemotherapy in PABC.[21] Second, this was a retrospective study as conducting randomized trial recruitment of pregnant women is not feasible. In contrast, the strength of this study is that it included the largest number of patients with PABC than those in previous studies. Additionally, this is the only study that matched age, histological grade, subtype, and treatment, and the variables were corrected using PSM.

5. Conclusions
Patients with PABC have worse prognosis than non-PABC patients despite adjusting for age, stage, molecular subtype, histological type/grade, and chemotherapy. This effect was the most significant in patients with the luminal B and TNBC subtypes. An increase in treatment should be considered for patients aged <35 years with PABC, especially luminal B or TNBC subtypes. Further research on PABC biology and prognosis, and optimized treatment by subtype are warranted.

Author contributions
Conceptualization: Hongki Gwak, Seong Hwan Kim.
Data curation: Hongki Gwak, Eun-Sook Lee, Min Ho Park, Seokwon Lee, Hyun Jo Youn, Seho Park, In Suck Suh.
Formal analysis: Hongki Gwak, Sang Seok Woo, Seong Hwan Kim.
Table 2

Multivariate analyses of factors associated with the overall survival of breast-cancer-specific survival in pregnancy-associated breast cancer patients.

|                          | Overall survival | Breast cancer-specific survival |
|--------------------------|------------------|--------------------------------|
|                          | Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value |
| Overall                  | 1.652 (1.280–2.132) | <.001 | 1.620 (1.250–2.100) | <.001 |
| Age                      |                  |      |                      |        |
| <35                      | 1.626 (1.146–2.307) | .006 | 1.594 (1.156–2.198) | .004  |
| ≥35                      | 1.787 (1.076–2.967) | .025 | 1.773 (1.134–2.772) | .012  |
| Operation                |                  |      |                      |        |
| BCS                      | 1.812 (1.084–3.030) | .023 | 1.814 (1.161–2.833) | .009  |
| Mastectomy               | 1.627 (1.144–2.314) | .007 | 1.576 (1.137–2.183) | .006  |
| Stage                    |                  |      |                      |        |
| I                        | 3.553 (1.167–10.821) | .026 | 3.006 (1.131–7.986) | .027  |
| II                       | 2.358 (1.285–4.327) | .006 | 2.100 (1.226–3.598) | .007  |
| III                      | 1.342 (0.914–1.969) | .133 | 1.388 (0.983–1.960) | .063  |
| IV                       | 2.472 (0.830–7.364) | .104 | 1.682 (0.636–4.449) | .294  |
| Tumor type               |                  |      |                      |        |
| IDC                      | 1.668 (1.250–2.225) | .001 | 1.657 (1.275–2.153) | <.001 |
| ILC                      | NA               | .001 | NA                  | .001  |
| Other                    | 3.677 (0.853–163.643) | <.001 | 1.955 (0.074–19.384) |        |
| Histological grade       |                  |      |                      |        |
| I                        | 1.431 (0.224–9.134) | .705 | 2.366 (0.517–10.838) | .267  |
| II                       | 1.452 (0.855–2.467) | .167 | 1.501 (0.928–2.428) | .098  |
| III                      | 1.741 (1.226–2.473) | .002 | 1.609 (1.171–2.211) | .003  |
| Subtype                  |                  |      |                      |        |
| Luminal A                | 2.387 (0.268–21.218) | .435 | 0.622 (0.124–3.130) | .565  |
| Luminal B (high Ki67)    | 2.386 (1.382–4.120) | .002 | 2.035 (1.209–3.427) | .008  |
| Luminal HER2             | 1.136 (0.420–3.084) | .739 | 1.125 (0.446–2.923) | .803  |
| HER2                     | 1.703 (0.791–3.929) | .166 | 1.789 (0.893–3.584) | .101  |
| TNBC                     | 1.573 (0.722–2.242) | .04  | 1.551 (1.054–2.281) | .026  |
| Chemotherapy             |                  |      |                      |        |
| Yes                      | 1.673 (1.253–2.235) | <.001 | 1.644 (1.266–2.136) | <.001 |
| No                       | 0.897 (0.200–3.966) | .879 | 0.010 (0.000–1.902) | .085  |
| Hormone therapy          |                  |      |                      |        |
| Yes                      | 2.276 (1.529–3.390) | <.001 | 1.612 (1.013–2.566) | .044  |
| No                       | 16.272 (3.085–85.811) | .001 | 47.190 (2.815–791.662) | .007  |

BCS = breast-conserving surgery, CI = confidence interval, HER2 = human epidermal growth factor receptor 2, IDC = invasive ductal carcinoma, ILC = invasive lobular carcinoma, TNBC = triple-negative breast cancer.

Funding acquisition: Seong Hwan Kim.
Investigation: Hongki Gwak.
Methodology: Hongki Gwak, Sang Seok Woo, Seong Hwan Kim.
Project administration: Hongki Gwak.
Resources: Hongki Gwak.
Software: Hongki Gwak.
Supervision: Seong Hwan Kim.
Validation: Hongki Gwak.
Visualization: Hongki Gwak.
Writing – original draft: Hongki Gwak.
Writing – review & editing: Seong Hwan Kim.

References
[1] Andersson TM, Johansson ALV, Hsieh CC, et al. Increasing incidence of pregnancy-associated breast cancer in Sweden. Obstet Gynecol. 2009;114:568–72.
[2] Merlo DF, Ceppi M, Filiberti R, et al. Breast cancer incidence trends in European women aged 20–39 years at diagnosis. Breast Cancer Res Treat. 2012;134:363–70.
[3] Lee GE, Mayer EL, Partridge A. Prognosis of pregnancy-associated breast cancer. Breast Cancer Res Treat. 2007;103:93–102.
[4] Johannson ALV, Andersson TM, Hsieh CC, et al. Tumor characteristics and prognosis in women with pregnancy-associated breast cancer. Int J Cancer. 2018;142:1343–54.
[5] Travers KF, Gammon MD, Abrahamson PE, et al. Association between reproductive factors and breast cancer survival in younger women. Breast Cancer Res Treat. 2007;103:93–102.
[6] Whiteman MK, Hills SD, Curtis KM, et al. Reproductive history and mortality after breast cancer diagnosis. Obstet Gynecol. 2004;104:146–54.
[7] Nagatsuura AK, Shimizu C, Takahashi F, et al. Impact of recent parity on histopathological tumor features and breast cancer outcome in premenopausal Japanese women. Breast Cancer Res Treat. 2013;138:941–50.
[8] Moller H, Purushotham A, Linklater KM, et al. Recent childbirth is an adverse prognostic factor in breast cancer and melanoma, but not in Hodgkin lymphoma. Eur J Cancer. 2013;49:3686–93.
[9] Olson SH, Zauber AG, Tang J, et al. Relation of time since last birth and parity to survival of young women with breast cancer. Epidemiology. 1998;9:669–71.
[10] De Mulder H, Laenen A, Wilders H, et al. Breast cancer subtype and survival by parity and time since last birth. Breast Cancer Res Treat. 2018;169:481–7.
[11] Iqbal J, Amir E, Rochon PA, et al. Association of the timing of pregnancy with survival in women with breast cancer. JAMA Oncol. 2017;3:659–65.
[12] Bae SY, Jung SP, Jung ES, et al. Clinical characteristics and prognosis of pregnancy-associated breast cancer: poor survival of Luminal B subtype. Oncology. 2018;95:163–9.
[13] Howlader N, Cronin KA, Kurian AW, et al. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018;27:1769–76.
[14] Thorne C, Lee AV. Cross talk between estrogen receptor and IGF signaling in normal mammary gland development and breast cancer. Breast Dis. 2003;17:105–14.
[15] Schedin P. Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer. 2006;6:281–91.
[16] Lohi S, Schmidt A, Gentilini O, et al. Breast cancer diagnosed during pregnancy: adapting recent advances in breast cancer care for pregnant patients. JAMA Oncol. 2015;1:1145–53.
[17] Amant F, von Minckwitz G, Han SN, et al. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol. 2013;31:2532–9.

[18] Schneider J, Lee HJ, Nam SJ, et al. Relative survival benefit by hormonal receptor status of adding Trastuzumab to Neoadjuvant Chemotherapy in breast cancer patients. J Breast Cancer. 2020;23:259–67.

[19] Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28:1700–12.

[20] Sacchini V, Norton L. Escalating de-escalation in breast cancer treatment. Breast Cancer Res Treat. 2022;195:85–90.

[21] Loibl S, Han SN, von Minckwitz G, et al. Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol. 2012;13:887–96.